Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nafamostat
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : H.C. Wainwright & Co.
Deal Size : $26.3 million
Deal Type : Private Placement
Details : The net proceeds will be used to advance Niyad (nafamostat), an investigational broad-spectrum serine protease inhibitor with anticoagulant, anti-inflammatory, mucus clearing and potential anti-viral activities, towards an FDA approval.
Product Name : Niyad
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 21, 2023
Lead Product(s) : Nafamostat
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : H.C. Wainwright & Co.
Deal Size : $26.3 million
Deal Type : Private Placement
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Alora Pharmaceuticals
Deal Size : $2.7 million
Deal Type : Divestment
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
Details : Under the divestment, Alora will accelerate the commercialization of Dsuvia (sufentanil), a synthetic opioid analgesic formulation for the management of acute pain.
Product Name : Dsuvia
Product Type : Controlled Substance
Upfront Cash : Undisclosed
May 04, 2023
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Alora Pharmaceuticals
Deal Size : $2.7 million
Deal Type : Divestment
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Alora Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Divestment
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals
Details : The divestment allows AcelRx to participate in the long-term value expected to be created by Alora as they expand the commercialization of Dsuvia (sufentanil citrate).
Product Name : Dsuvia
Product Type : Controlled Substance
Upfront Cash : Undisclosed
March 14, 2023
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Alora Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Divestment
Lead Product(s) : Nafamostat
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study
Details : Niyad (a lyophilized formulation of nafamostat), an investigational broad-spectrum serine protease inhibitor with anticoagulant, anti-inflammatory, mucus clearing and potential anti-viral activities, towards an FDA approval.
Product Name : Niyad
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2023
Lead Product(s) : Nafamostat
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DSUVIA (sufentanil), an opioid analgesic, is indicated for use in adults for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Product Name : Dsuvia
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 31, 2022
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant
Details : DZUVEO® (sufentanil sublingual tablet, 30 mcg), a novel sublingual approach to acute pain management, was designed to provide rapid analgesia via a non-invasive route and to eliminate high peak plasma levels and provide longer duration of action.
Product Name : Dsuvia
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 27, 2022
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dsuvia (sufentanil) is an opioid analgesic previously only marketed for IV and epidural anesthesia and analgesia, is indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequa...
Product Name : Dsuvia
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 26, 2022
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DSUVIA, known as DZUVEO (sufentanil citrate) in Europe, is indicated for use in adults in certified medically supervised healthcare settings, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatmen...
Product Name : Dsuvia
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 08, 2022
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study found that Dzuveo (Sufentanil Citrate) lowered the opioid dose required by patients in the post-anesthesia care unit (PACU) by more than five-fold compared to standard intravenous opioid administration.
Product Name : Dsuvia
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 05, 2022
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®
Details : DSUVIA (sufentanil sublingual tablet), known as DZUVEO® in Europe, is indicated for use in adultsfor the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Product Name : Dsuvia
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 19, 2022
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable